Advertisement
To participate in the live conference call, please dial 800-510-0146 (U.S.callers) or 617-614-3449 (international), and provide passcode 84349393. Alive webcast of the call will also be available athttp://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=1768582. Pleaseallow extra time prior to the webcast to register, download and install anynecessary audio software.
Advertisement
The webcast will be archived for 30 days, and a telephone replay of thecall will be available for seven days beginning at 10:30 AM ET on March 4th at888-286-8010 (U.S. callers) or 617-801-6888 (international callers), usingpasscode 90757979.
About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein processdevelopment and manufacturing experience and a proprietary protein platformaimed at niche markets with unmet medical needs. For more information, pleasevisit www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made pursuantto provisions of Section 21E of the Securities Exchange Act of 1934. Investorsare cautioned that such statements in this release, including statementsrelating to planned clinical study design, regulatory and business strategies,plans and objectives of management and growth opportunities for existing orproposed products, constitute forward-looking statements which involve risksand uncertainties that could cause actual results to differ materially fromthose anticipated by the forward-looking statements. The risks anduncertainties include, without limitation, risks that product candidates mayfail in the clinic or may not be successfully marketed or manufactured, we maylack financial resources to complete development of product candidates, theFDA may interpret the results of studies differently than us, competingproducts may be more successful, demand for new pharmaceutical products maydecrease, the biopharmaceutical industry may experience negative markettrends, our entrance into the follow on biologics market may be unsuccessful,our common stock could be delisted from the Nasdaq Global Market and otherrisks and challenges detailed in our filings with the U.S. Securities andExchange Commission, including our Quarterly Report on Form 10-Q for thequarter ended September 30, 2007. Readers are cautioned not to place unduereliance on any forward-looking statements which speak only as of the date ofthis release. We undertake no obligation to publicly release the results ofany revisions to these forward-looking statements that may be made to reflectevents or circumstances that occur after the date of this release or toreflect the occurrence of unanticipated events.Investor Relations Contact: Brian Ritchie - FD 212-850-5683 [email protected] Corporate Communications Contact: John Procter - Gibraltar Associates 202-879-5808 [email protected]
SOURCE Insmed Inc.